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INTRODUCTION
Since inception, the International Centre for 
Science in Drug Policy (ICSDP) has sought to 
ensure that policy responses to the many prob-
lems posed by illicit drugs are informed by the 
best available scientific evidence. 
State of the Evidence: Cannabis Use and Regulation 
is the ICSDP’s contribution to the growing 
global conversation on cannabis. This report 
should be read in tandem with Using Evidence to 
Talk About Cannabis, a complementary guide to 
having evidence-based discussions on cannabis 
use and regulation.
The regulation of recreational cannabis mar-
kets has become an increasingly important 
policy issue in a number of jurisdictions. Col-
orado and Washington State made headlines 
in 2012 when they became the first jurisdic-
tions in the world to legalize and regulate the 
adult use and sale of cannabis for non-medical 
purposes. In 2013, Uruguay became the first 
country to legalize and regulate recreational 
cannabis markets. Momentum towards regu-
lation continued in the United States in 2014 
with successful ballot initiatives in Alaska, 
Oregon, and the District of Columbia. Global-
ly, the issue of cannabis regulation is front and 
center in a growing number of jurisdictions, 
including Canada, Jamaica, Italy, Spain, several 
Latin American countries, and a number of 
additional U.S. states, including California, set 
to vote on legalization initiatives in 2016. 
Unsurprisingly, given the robust global conver-
sation around the regulation of recreational 
cannabis markets, claims about the impacts of 
cannabis use and regulation are increasingly 
part of the public discourse. Unfortunately, 
though, these claims are often unsupported 
by the available scientific evidence. Another 
reoccurring problem in the public discourse 
is the selective inclusion of research studies 
based on their support for a predetermined 
narrative. The intentional exclusion of studies 
with contradictory findings does not allow for 
an objective review and analysis of all the evi-
dence. This “cherry picking” of the evidence is 
a routine practice that distorts public under-
standing. By outlining the current state of all 
the scientific evidence on common cannabis 
claims, State of the Evidence: Cannabis Use and 
Regulation strives to ensure that evidence, rath-
er than rhetoric, plays a central role in policy-
making around this important issue. 
The harms of misrepresenting the scientific 
evidence on cannabis should not be over-
looked. Given that policy decisions are influ-
enced by public opinion and media reports, 
public discourse needs to be well informed. 
By addressing knowledge gaps with scientific 
findings, the ICSDP hopes to dispel myths 
about cannabis use and regulation, and ensure 
that the scientific evidence on these topics is 
accurately represented. Only then can evi-
dence-based policy decisions be made. 
Readers of this report will notice three repeat-
ing themes emerge through the discussion of 
the scientific evidence on common cannabis 
claims. 
First, many of the claims confuse correlation 
and causation. Although scientific evidence 
may find associations between two events, 
this does not indicate that one necessarily 
caused the other. Put simply, correlation does 
not equal causation. This is a commonly made 
mistake when interpreting scientific evidence 
in all fields, and is unsurprisingly a recurring 
source of confusion in the discourse on canna-
bis use and regulation. 
Common Claims on Cannabis Regulation presents 
evidence on frequently heard claims about the 
impacts of cannabis regulation, including the 
impact of regulation on cannabis availability, 
impaired driving, the use of cannabis, drug 
crime, drug tourism, and “Big Marijuana.”
For each claim, the relevant available scientif-
ic evidence is presented and the strength of 
the scientific evidence in support of the claim 
is determined. Readers will notice that none 
of the claims are strongly supported by the 
scientific evidence, reinforcing the significant 
misrepresentation of evidence on cannabis use 
and regulation. 
We hope that the evidence contained in this 
report meaningfully contributes to the global 
conversation around cannabis policy and helps 
policymakers, as well as general readers, sepa-
rate scientific evidence from conjecture.
Second, for several of these claims, the in-
ability to control for a range of variables 
(“confounders”) means that in many cases, we 
cannot conclude that a particular outcome was 
caused by cannabis use or regulation. Unless 
scientists can remove all other possible expla-
nations, the evidence cannot conclusively say 
that one specific explanation is true.
Third, many of the claims cannot be made 
conclusively as there is insufficient evidence to 
support them. Findings from a single study or 
a small sample cannot be generalized to entire 
populations. This is especially pronounced for 
claims related to cannabis regulation, as not 
enough time has passed since the regulation 
of recreational cannabis in Colorado, Wash-
ington State, and Uruguay to examine many of 
the impacts of these policy changes. 
These three common pitfalls are important to 
take into account when reading media reports 
and advocacy materials that suggest scientists 
have conclusively made some finding related 
to cannabis use or regulation. In many cases, 
due to the reasons outlined above, this will 
actually result in a misrepresentation of the 
scientific evidence. 
State of the Evidence: Cannabis Use and Regulation 
is comprised of two sections: Common Claims 
on Cannabis Use and Common Claims on Cannabis 
Regulation. 
Common Claims on Cannabis Use presents evi-
dence on frequently heard claims about can-
nabis use, including claims on the addictive 
potential of cannabis, cannabis as a “gateway” 
drug, the potency of cannabis, and the impact 
of cannabis use on the lungs, heart, and brain 
(in terms of IQ, cognitive functioning, and risk 
of schizophrenia). 
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METHODS
We undertook a review of the available scientific literature on the topic of cannabis use and 
regulation. First, two co-authors (DW, TMW) identified common claims about cannabis put 
forward by media outlets, government agencies, political leaders, and third-party advocacy orga-
nizations. For each claim, two authors (TMW, DW) undertook a thorough review of all scien-
tific peer-reviewed studies, as well as non-peer reviewed scientific studies (i.e., ‘grey literature’) 
on these topics. This process included searching major online academic databases, the Internet, 
medical library databases, and the citation lists of relevant scientific studies to identify the most 
up-to-date scientific evidence on cannabis use and regulation. All authors (DW, TMW, NM) 
then undertook a quality assessment process for the scientific literature related to each claim to 
determine the overall strength of the scientific evidence. Finally, all authors (DW, TMW, NM) 
contributed to the drafting of these findings in the text of this report and two authors (DW, 
NM) drafted the response sheets contained in Using Evidence to Talk About Cannabis. 
The complete methodology for this report, including specific databases searched, keywords 
used, and quality assessment protocols, are available online at http://www.icsdp.org/cannabis_
claims_methods.
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COMMON CLAIMS ON
CANNABIS USE
COMMON CLAIMS ON CANNABIS USE
CLAIM
STRENGTH OF 
SUPPORTING 
EVIDENCE
BOTTOM LINE
“Cannabis [is] as addic-
tive as heroin.”
Weak
A lifetime of cannabis use carries a low risk of 
dependence (9%), while the risk of cannabis 
dependence is very low among those who re-
port using it for one year (2%) or even 10 years 
(5.9%). This is much lower than the estimated 
lifetime risk of dependence to heroin (23.1%).
“[D]id you know that 
marijuana is on aver-
age 300 to 400 percent 
stronger than it was thir-
ty years ago?”
Moderate
Although this claim overstates the existing evi-
dence, studies do suggest that there have been 
increases in THC potency over time in some 
jurisdictions.
“I’m opposed to legaliz-
ing marijuana because it 
acts as a gateway drug.”
Weak
Evidence to date does not support the claim 
that cannabis use causes subsequent use of 
“harder” drugs.
Cannabis use “can cause 
potentially lethal damage 
to the heart and arteries.”
Weak
There is little evidence to suggest that cannabis 
use can cause lethal damage to the heart, nor is 
there clear evidence of an association between 
cannabis use and cancer.
Cannabis use lowers IQ 
by up to 8 points. Weak
There is little scientific evidence suggesting that 
cannabis use is associated with declines in IQ.
Cannabis use impairs 
cognitive function. Moderate
While the evidence suggests that cannabis use 
(particularly among youth) likely impacts cog-
nitive function, the evidence to date remains 
inconsistent regarding the severity, persistence, 
and reversibility of these cognitive effects.
“[Cannabis] is a drug that 
can result [in] serious, 
long-term consequences, 
like schizophrenia.”
Weak
While scientific evidence supports an associa-
tion between cannabis use and schizophrenia, a 
causal relationship has not been established.
8 9
CLAIM: “Cannabis [is] as addictive as heroin.” – Daily Telegraph (Fox, 2014)
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: A lifetime of cannabis use carries a low risk of dependence (9%), while the 
risk of cannabis dependence is very low among those who report using it for one year (2%) or 
even 10 years (5.9%). This is much lower than the estimated lifetime risk of dependence to 
heroin (23.1%).
Drug dependence, also commonly referred 
to as addiction, can be a serious consequence 
of drug use. However, not all drugs have the 
same addictive potential, meaning that some 
drugs – like heroin – are more likely to lead to 
addiction than others. With respect to canna-
bis, this drug is associated with a lower risk of 
dependence compared to so-called “harder” 
illicit drugs, such as cocaine and heroin, as 
well as two regulated substances – nicotine 
and alcohol. 
Lopez-Quintero and colleagues examined 
multi-wave data from the National Epidemi-
ologic Survey on Alcohol and Related Condi-
tions, a U.S. nationally representative survey 
of people aged 18 and over (sample size: 7,389 
cannabis users) (Lopez-Quintero et al., 2011). 
These authors found that the probability of 
dependence after the first year of use was 
about 2% (i.e., very low) for nicotine, alco-
hol, and cannabis users; for cocaine users, the 
probability was 7.1%. After a decade of use, 
the probabilities for dependence were higher 
for users of nicotine (15.6%), cocaine (14.8%), 
and alcohol (11%) compared to cannabis users 
(5.9%). The lifetime probability of becoming 
cannabis dependent was estimated at 8.9%; 
that is, fewer than 9% of lifetime cannabis 
users report drug dependence. This 9% prob-
ability of cannabis dependence is most often 
cited in the literature, most recently in two 
major scientific review articles on the impact 
of cannabis (Hall, 2014; Volkow et al., 2014). 
This figure is considerably lower than estimat-
ed lifetime probabilities for users of nicotine 
(67.5%), alcohol (22.7%), and cocaine (20.9%). 
The lifetime probability of becoming hero-
in-dependent has previously been estimated at 
23.1% and 35.5% (Anthony et al., 1994). 
One other claim regarding cannabis depen-
dence that has been frequently cited is that 
the probability of dependence may increase 
to 1 in 6 for those who initiate cannabis use in 
adolescence, and that this risk may increase to 
25-50% among people who use cannabis daily 
(Hall, 2009; Volkow et al., 2014). This suggests 
that the age of onset of cannabis use and the 
frequency or regularity of use influences the 
risk that an individual will become dependent. 
STATE OF THE EVIDENCE:
The source of this ‘1 in 6’ estimate is a paper 
by Wagner et al., which reported findings from 
the National Comorbidity Survey (NCS) that 
included 8,098 participants who comprised a 
nationally representative sample of the U.S. 
population aged 15-54 (Wagner and Anthony, 
2002). These authors reported that 4.2% of 
participants qualified for “lifetime diagnosis of 
cannabis dependence” based on DSM-III-R 
criteria. While approximately 46% of the 
sample had ever used cannabis, approximately 
9% had developed dependence. Wagner et al. 
conducted additional statistical analyses to 
find age- and time-specific estimates of use 
initiation for cannabis (as well as alcohol and 
cocaine). The authors reported that most cases 
of cannabis dependence occur at younger ages 
(between 15-25 years of age), with peak val-
ues at age 17-18. However, the developmental 
window of risk for cannabis dependence was 
nearly closed by age 30 (Wagner and Anthony, 
2002). Further, after 10 years since the first use 
of cannabis, the risk of dependence dropped 
to near zero (meanwhile, the risk of progres-
sion to alcohol dependence lasts many more 
years since first alcohol use). 
While data from large cross-sectional sur-
veys like those mentioned here are valuable 
in estimating levels of cannabis dependence, 
cross-sectional data do not allow for causal 
interpretations. Therefore, we must be very 
cautious regarding any blanket statement 
that cannabis leads to addiction. The evidence 
shows that the vast majority – over 90% – of 
cannabis users do not become dependent. 
Indeed, Anthony and colleagues (1994) even 
stated their findings in the following way: 
“For every user with a history of cannabis 
dependence, there were 10 users who had not 
become dependent” (Anthony et al., 1994). 
Again, compared to users of nicotine and 
alcohol, fewer users of cannabis will become 
dependent over time. 
 
The common understanding of addiction – 
simply requiring a substance to function – is 
an oversimplification. There are multiple 
working definitions of drug addiction (also 
called substance use disorder); in one defini-
tion, drug addiction is defined as the compul-
sive use of a drug despite adverse consequenc-
es (Nestler, 1992). With this in mind, addiction 
to different substances is not necessarily 
related to equivalent harms. For example, 
many people meet the criteria for caffeine 
addiction, but this is generally not seen as a 
major public health problem. The symptoms 
for cannabis withdrawal have been character-
ized as primarily psychological (rather than 
physical), and include non-life threatening 
symptoms (craving, irritability, nervousness/
tension, restlessness, depression, anger, sleep 
difficulty, strange dreams, decreased appetite, 
and headache) (Copersino et al., 2006; Kouri 
and Pope Jr, 2000). By comparison, with-
drawal symptoms for addiction to alcohol or 
heroin have been shown to be severe (Olmedo 
and Hoffman, 2000; Redmond Jr and Krystal, 
1984; Swift and Stout, 1992) and, in the case of 
alcohol, life-threatening (Trevisan et al., 1997). 
This implies that cannabis dependence is less 
severe than that associated with other major 
illegal and legal drugs.
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CLAIM: “[D]id you know that marijuana is on average 300 to 400 percent stronger than it was 
thirty years ago?” – Health Canada advertisement 1
STRENGTH OF SUPPORTING EVIDENCE: Moderate
BOTTOM LINE: Although this claim overstates the existing evidence, studies do suggest that 
there have been increases in THC potency over time in some jurisdictions.
Tetrahydrocannabinol (THC) is the main psy-
choactive element in cannabis and thus THC 
levels have been studied as the primary marker 
of cannabis potency. There is evidence to sup-
port the claim that cannabis potency in some 
regions has increased in recent decades. 
McLaren and colleagues found noticeable 
variation in cannabis potency between samples 
and within years (McLaren et al., 2008). For 
instance, while they found that potency in the 
U.S. seemed to have doubled (2% in 1980 to 
4.5% in 1997) based on testing THC in confis-
cated cannabis, significant increases were not 
reported for European countries other than 
the United Kingdom and the Netherlands. 
Slight increases have also been reported in 
Australia (Hall and Swift, 2000).
In a more recent study, Mehmedic and col-
leagues reported U.S. data from 46,211 canna-
bis samples seized and analyzed between 1993 
and 2008 (Mehmedic et al., 2010). They found 
that during this timeframe THC content 
across cannabis preparations increased from 
3.4% to 8.8%, and that the increase appeared 
due to increases in nondomestic cannabis (i.e., 
an increase in the supply of cannabis imported 
into the U.S.). 
In a review, Volkow and colleagues (2014) cited 
that THC content detected in samples of can-
nabis confiscated in the U.S. increased from 
approximately 3% to 12% (i.e., 300%) from the 
1980s up to 2012 (Volkow et al., 2014). Giv-
en that this review from the U.S. is the only 
evidence for a 300% increase in potency, the 
claim that cannabis potency has increased by 
300% to 400% on average across all jurisdic-
tions overstates the existing scientific evi-
dence. It is noteworthy that the observed in-
creases of 300% in the United States occurred 
during a period of massive budgets allocated 
towards a primarily enforcement-based drug 
supply reduction approach (Miron, 2008). 
This suggests that enforcement-based ap-
proaches to reducing cannabis supply are likely 
limited. Moreover, trends towards increasing 
potency are not merely demand-driven, but 
are primarily a result of criminal market eco-
nomics. Given that stronger strains provide 
higher profits per unit weight, and that crim-
inal markets have no regulatory structures to 
set potency limits, the illicit nature of canna-
bis likely played a role in driving up potency.
As with all estimates of illicit products, there 
is the potential that methodological issues 
may be at play when determining estimates. 
McLaren and colleagues (2008) mention, for 
example, that cannabis samples that are test-
ed tend to be small and that it is not always 
clear which part of the plant has been tested 
(McLaren et al., 2008). This is important given 
STATE OF THE EVIDENCE:
1 Accessed March 6th 2015 from www.youtube.com/watch?v=VEuCvUdHDNA
that parts of the cannabis plant have higher 
reservoirs of THC. The extent to which police 
seizures of cannabis are representative of the 
larger market is also unclear (Arkes et al., 
2008), suggesting that we may not be able to 
make market wide generalizations based on 
seized samples.
Other factors beyond THC content are 
important when considering the impact of 
potency. For example, mixing cannabis with 
tobacco – a common practice when smoking 
cannabis in many parts of the world – dilutes 
THC potency. The amount of active THC 
actually absorbed can also vary considerably 
based on the mode by which cannabis is con-
sumed. Simply assessing THC levels paints an 
incomplete picture of the impact of cannabis 
potency. 
A related issue is the actual health impact of 
any increases in THC content. Experts have 
suggested that increased THC potency may be 
linked to adverse health and/or mental health 
effects and consequences, including visits to 
emergency rooms (Hall, 2014; Volkow et al., 
2014); however, this evidence is preliminary 
and highly equivocal at present. Indeed, Mc-
Laren and colleagues also report in their re-
view that claims about “adverse mental health 
effects of cannabis contamination” were un-
supported by the available evidence (McLaren 
et al., 2008). Briefly, this suggests that increas-
es in cannabis potency and subsequent toxicity 
(i.e., contamination) lack equivocal evidence. 
By contrast, there is burgeoning (though pre-
liminary) evidence that some cannabis users 
may respond to higher THC content by reduc-
ing the volume of cannabis that they consume, 
which may in turn lessen potential adverse 
effects (Van der Pol et al., 2014). 
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CLAIM: “I’m opposed to legalizing marijuana because it acts as a gateway drug.” – Enrique Peña 
Nieto, President of Mexico 2
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: Evidence to date does not support the claim that cannabis use causes subse-
quent use of “harder” drugs.
The claim that cannabis acts as a “gateway 
drug” has been debated and tested by scien-
tists in various ways across settings. To date, 
studies have shown relatively strong support 
for the use of cannabis generally preceding 
the use of other illicit drugs. However, studies 
have not shown that the “gateway” explana-
tion is supported by the scientific evidence. 
Put another way, research has not established 
a causal relationship between using cannabis 
and the increased risk of using “harder” drugs 
such as cocaine and heroin.
Degenhardt and colleagues conducted a study 
to test the “gateway” theory using data on the 
initiation of use of alcohol, tobacco, canna-
bis, and other illicit drugs from a consistent 
set of epidemiological surveys from 17 coun-
tries (Degenhardt et al., 2010). These authors 
found variation across countries and cohorts 
regarding the strength of the association 
between so-called “gateway” substances and 
the use of other drugs. So, for example, the 
authors found that in some countries, alcohol/
tobacco use was more strongly linked to later 
use of other illicit drugs than cannabis. They 
also observed so-called “gateway violations”; 
trends whereby “harder” illicit drugs were used 
before cannabis. 
Although we cannot derive causal explana-
tions from this study, these data cast serious 
doubt on claims that cannabis is a “gateway” 
drug, especially when we consider different 
contexts across the globe. That being said, the 
widely observed sequence or ordering of drug 
use – i.e., alcohol/tobacco before cannabis, and 
cannabis before other illicit drugs – does seem 
to hold with few exceptions. In a review, Hall 
(2014) stated that the order of use with canna-
bis and other illicit drugs is one of “the most 
consistent findings in epidemiological studies 
of drug use in young adults” (p. 7). In another 
review, Volkow and colleagues included some 
studies that used animal subjects and found 
evidence that cannabis use can prime the brain 
for “enhanced responses to other drugs” (Vol-
kow et al., 2014); however, these authors also 
mentioned that other substances, like nico-
tine and alcohol, have been linked to similar 
effects. It is important to note that despite 
these findings, the authors of these two recent 
reviews (as well as many scientists working on 
these issues) are very cautious regarding the 
validity of the “gateway” theory. Both reviews 
noted that interpretations of available data on 
cannabis and other drug use have been con-
tested and that there are multiple interpreta-
tions for the general pattern of cannabis use 
before “harder” drugs. 
Hall and Lynskey highlighted drug use pat-
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2 Reported in The Washington Post. Accessed March 6th 2015 from http://www.washingtonpost.com/blogs/world-
views/wp/2013/02/06/mexicos-president-opposes-legalizing-marijuana-calls-it-a-gateway-drug/ 
terns documented in the literature that could 
support a “gateway” role for cannabis, but also 
outlined key competing explanations for these 
observed patterns (Hall and Lynskey, 2005). 
These include: 
1. cannabis and other drugs being part of a 
shared illicit drug market; 
2. certain characteristics of cannabis users 
(e.g., risk-taking) explaining the patterns 
of both cannabis and other drug use (i.e., 
factors like mental health confounding 
the relationship between cannabis use and 
other drug use); and
3. use of cannabis altering brain function in a 
way that increases the likelihood of other 
drug use. 
To investigate these potential pathways, 
Morral and colleagues built a statistical mod-
el based on U.S. population drug use survey 
data. They tested data on the risk, order, and 
dose-response relationships related to canna-
bis use and other drugs. While they could not 
unequivocally disprove the cannabis “gateway” 
theory, they nevertheless demonstrated “that 
the primary evidence supporting gateway 
effects is equally consistent with an alterna-
tive model of adolescent drug use initiation in 
which use, per se, of marijuana has no effect 
on the later use of hard drugs” (Morral et al., 
2002). 
Studies like that by Degenhardt and colleagues 
have consistently shown that there are few 
exceptions to an age-of-onset relationship 
(Degenhardt et al., 2010). In other words, the 
earlier one tries drugs, the more likely they are 
to subsequently use other drugs. A key impli-
cation of this finding is to focus prevention 
efforts not so much on one particular type of 
drug such as cannabis, but on addressing the 
risk of early use, as the age of onset appears to 
have much more of an impact on the future 
drug-related harms that an individual experi-
ences compared with the impact of cannabis 
use.
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CLAIM: Cannabis use “can cause potentially lethal damage to the heart and arteries.” – World 
Federation Against Drugs 3
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: There is little evidence to suggest that cannabis use can cause lethal damage 
to the heart, nor is there clear evidence of an association between cannabis use and cancer.
There is little research regarding the impact 
of cannabis use on the heart and cardiovascu-
lar functioning. A recent review reported that 
the mechanisms behind cannabis effects on 
the cardiovascular system are “complex and 
not fully understood” (Volkow et al., 2014). 
Although cannabis use has been found to be 
associated with acute effects that can trigger 
events like heart attack and stroke (Jouanjus 
et al., 2014; Thomas et al., 2014), clear causal 
linkages have not been established. Research 
has also tended to suggest that potentially 
risky cardiovascular effects from cannabis 
smoking are more likely to occur in older 
adults (Hall, 2014). In sum, there is a need 
for ongoing research on these health effects, 
but claims purporting “lethal damage” related 
to cannabis use are overstating the scientific 
research.
With respect to the impact of cannabis on 
physical health, studies have reported that 
smoking cannabis is associated with various 
respiratory-related problems, including injury 
to the large airways and symptoms of chronic 
bronchitis (Gordon et al., 2013; Tashkin, 2013; 
Tashkin et al., 2002). However, Tashkin also 
reported no evidence of a strong association 
between cannabis smoking and chronic ob-
structive pulmonary disease or several other 
pulmonary conditions (Tashkin, 2013). Inter-
estingly, a 20-year study involving a cohort of 
5,115 participants found that low, occasional 
cannabis use was actually associated with 
increased, rather than decreased, pulmonary 
function (Pletcher et al., 2012). In a recent re-
view, Hall summarized the current evidence on 
the effects of long-term cannabis smoking on 
respiratory function as “unclear” (Hall, 2014). 
The measurement of respiratory risks associ-
ated with cannabis use are substantially com-
plicated by the routine practice of smoking 
cannabis and tobacco together. The respira-
tory harms and carcinogenic risks of tobacco 
are not contested, and certainly remain when 
combined with cannabis. Importantly, po-
tential respiratory harms can be minimized 
or eliminated by consuming cannabis using 
methods other than smoking. Vaporizing, for 
example, is thought to reduce these harms sig-
nificantly, and ingesting cannabis (via edibles) 
eliminates them entirely (Abrams et al., 2007; 
Earlywine and Barnwell, 2007; Hazekamp et 
al., 2006). 
The impact of cannabis smoking on the devel-
opment of lung cancer also remains unclear. 
While Hashibe and colleagues (2006) ob-
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3 From the title of a post on the World Federation Against Drugs website, linking to a study on cannabis smoking 
and cardiovascular problems. Accessed March 8th 2015 from http://wfad.se/latest-news/1-articles/4724-smoking-can-
nabis-can-cause-lethal-damage-to-heart
served an association between long-term can-
nabis smoking and lung cancer, this associa-
tion was non-significant when the results were 
adjusted for the impact of cigarette smoking 
and several other confounders (Hashibe et al., 
2006). 
 
It is worth noting that risks of morbidity and 
mortality associated with use of tobacco and 
alcohol are much higher than those associated 
with cannabis use. For example, evidence has 
found far greater risk of lung problems among 
tobacco users compared to regular cannabis 
users (Tashkin, 2013). 
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CLAIM: Cannabis use lowers IQ by up to 8 points.
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: There is little scientific evidence suggesting that cannabis use is associated 
with declines in IQ.
In recent years, the claim that cannabis use 
leads to significantly lower IQ has often 
been repeated, with an 8-point drop in IQ 
sometimes mentioned. One study in partic-
ular authored by Meier and colleagues (2012) 
is frequently cited as supporting evidence 
(Meier et al., 2012). However, the strength of 
this study’s findings has been questioned and 
newer evidence suggests that other substance 
use may have a greater impact on IQ. Indeed, 
a re-review of the data presented by Meier and 
colleagues, conducted by Rogeberg (Rogeberg, 
2013), suggests that the association between 
cannabis use and IQ decline can actually be 
explained (i.e., confounded by) by the socio-
economic status of participants, rather than by 
cannabis use itself.
The article by Meier and colleagues was based 
on data from participants in the Dunedin 
Study, a longitudinal investigation that fol-
lowed a cohort of individuals (n = 1,037) born 
in 1972/1973 in New Zealand until the age of 
38 (Meier et al., 2012). One of the main results 
reported was that “persistent cannabis depen-
dence” was associated with decline on most 
IQ subtests. By contrast, people who initiated 
cannabis use in adulthood did not show the 
same IQ declines. It was also reported that 
quitting cannabis use “did not fully restore 
neuropsychological functioning” among ado-
lescent-onset former persistent users. While 
these are intriguing findings, basing general 
claims regarding the impact of cannabis use on 
IQ on the results of one study – even a rela-
tively well-designed prospective cohort study 
– is problematic, particularly when the major 
claim (i.e., an 8-point drop in IQ as a result of 
cannabis use) was observed among only a very 
small subsample (n = 38) of participants, repre-
senting 0.037% of the total sample. 
Indeed, findings from a more recent prospec-
tive cohort study with a larger sample suggest 
an alternative explanation to these findings. 
Mokrysz and colleagues examined IQ test 
scores at ages 8 and 15 among participants 
(born 1991/1992) in the Avon Longitudinal 
Study of Parents and Children cohort in the 
United Kingdom (Mokrysz et al., 2014). Out 
of the full sample (n = 2,612; over twice as large 
as the Dunedin cohort), 24% reported using 
cannabis at least once by age 15. While those 
who used cannabis more than 100 times saw 
a significant IQ decline of over 3 points com-
pared to people who never used the drug, this 
effect disappeared after other key factors (e.g., 
sex, socioeconomic status, and other sub-
stance use) were taken into account. Addition-
ally, alcohol use was associated with IQ decline 
and actually explained most of the variance in 
the IQ changes that had been linked to canna-
bis use (i.e., the association between cannabis 
and IQ decline was confounded by alcohol 
use). Mokrysz and colleagues concluded that 
the age of substance use, rather than cannabis 
use per se, may be responsible for poorer neu-
ropsychological outcomes. These authors also 
stated the following (emphasis added):
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The findings do not support the hy-
pothesis that cannabis use in adoles-
cence leads to persistent decline in 
cognitive functioning, once other possi-
ble confounding variables are accounted for. 
The finding that moderate but not heavier 
alcohol use was associated with IQ decline 
may relate to a detrimental effect of alcohol 
use in adolescence, warranting further inves-
tigation. (Mokrysz et al., 2014)
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CLAIM: Cannabis use impairs cognitive function.
STRENGTH OF SUPPORTING EVIDENCE: Moderate
BOTTOM LINE: While the evidence suggests that cannabis use (particularly among youth) 
likely impacts cognitive function, the evidence to date remains inconsistent regarding the sever-
ity, persistence, and reversibility of these cognitive effects.
There are concerns that cannabis use, espe-
cially when initiated in adolescence, may lead 
to various forms of cognitive impairment. For 
example, a recent Health Canada advertise-
ment flashed “loss of memory” and “learning 
problems” on the screen (Health Canada, 
2014). The U.S. National Institute on Drug 
Abuse has warned parents that cannabis use 
“has negative effects on attention, motivation, 
memory, and learning that can persist after the 
drug’s immediate effects wear off – especially 
in regular users” (NIDA, 2014). While there is 
moderate evidence to support a general claim 
that early-onset and sustained cannabis use 
is associated with certain cognitive deficits, 
there remain important gaps in our knowledge 
regarding the full range of effects and their 
reversibility.
There is a fairly large though quite mixed 
literature about the effects of cannabis use on 
cognitive functioning and related outcomes. 
Recent reviews by Volkow and Hall summarize 
a number of studies that report associations 
between heavy, long-term cannabis use and 
cognitive impairments in memory, attention, 
and verbal learning (Hall, 2014; Volkow et al., 
2014). Crane and colleagues also conducted a 
comprehensive review and noted that recent 
and previous literature has shown that the 
acute effects of cannabis intoxication (i.e., 
currently ‘high’) are associated with short-term 
decreases in learning and memory; an unsur-
prising finding given that these effects occur 
during intoxication (Crane et al., 2013). Fur-
ther, while declines in cognitive function have 
been observed, Hall et al. note that “[i]t still 
remains unclear whether cognitive function re-
covers fully after cessation of long-term canna-
bis use” (Hall, 2014). In general, findings across 
studies have been inconsistent in terms of the 
nature of various cognitive deficits related to 
cannabis use, as well as their persistence over 
time. 
It is worth adding that claims about the effect 
of cannabis use on cognitive functioning ap-
pear related to other claims about educational 
attainment and social functioning – that is, 
claims are also often made that cannabis use 
leads to school failure, later unemployment, 
problems with life satisfaction, and other poor 
outcomes or psychosocial harms. The evidence 
is weaker when it comes to establishing clear 
causal associations on these issues (Fergusson 
and Boden, 2008; Townsend et al., 2007). That 
is because it is not possible to fully control 
for a host of potential confounders, such as 
other substance use or socioeconomic status, 
that may play a role in observed relationships. 
Perhaps most noteworthy is that a system-
atic review of all longitudinal, peer-reviewed 
scientific studies on this topic found that the 
evidence did not support a causal relationship 
between cannabis use by young people and 
various psychosocial harms (Macleod et al., 
2004). Indeed, a study by Verweij et al. investi-
gated educational attainment among a sample 
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of twins (Verweij et al., 2013). Hall et al. sum-
marize as follows: 
An analysis of twins who were discordant 
for early cannabis use [e.g., one used while 
the other didn’t] found no difference in risk 
of early school-leaving between the twins 
who did and did not use cannabis, suggesting 
that the association was explained by shared 
genetic and environmental risk factors. 
These findings are supported by two earli-
er analyses of US twin-study data. (Hall, 
2014)
The inconsistency across the scientific litera-
ture on this topic is likely related to method-
ological differences in the studies (e.g., sam-
ples, doses, cannabis use histories), as well as 
the lack of adequate adjustment for confound-
ers. Both Hall and Crane note that, over time, 
studies in this field have become more system-
atic and methodologically sound (Crane et al., 
2013; Hall, 2014). At present, though, there is 
little evidence that cannabis use causes long-
term, irreversible declines in cognitive func-
tion, as opposed to the inevitable impairment 
related to intoxication.
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CLAIM: “[Cannabis] is a drug that can result [in] serious, long-term consequences, like schizo-
phrenia.” – Kevin Sabet, Smart Approaches to Marijuana (Baca, 2015)
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: While scientific evidence supports an association between cannabis use and 
schizophrenia, a causal relationship has not been established.
On balance, the evidence has established an 
association between cannabis use and psychot-
ic symptoms associated with schizophrenia. 
However, the scientific literature does not sug-
gest that there is a causal relationship between 
cannabis use and schizophrenia. 
Importantly, if cannabis use caused schizo-
phrenia, we would expect to see increases in 
incidence as rates of cannabis use have in-
creased, but this trend has not been observed 
(Hall, 2014). To that end, one UK-based study 
reported that, given that cannabis use has 
increased fourfold among the UK population 
between the early 1970s to 2002, there should 
be a corresponding 29% increase in cases of 
schizophrenia among men, and 12% increase 
among women between 1990 and 2010 (Hick-
man et al., 2007). Instead, in the period during 
which these increases were estimated to in-
crease the most (1996-2005), it was found that 
annual cases of schizophrenia in the UK were 
either stable or declining (Frisher et al., 2009). 
These findings strongly suggest that cannabis 
use does not cause schizophrenia.
An older study with a large sample (n = 45,570) 
of Swedish male conscripts found that par-
ticipants who had tried cannabis by 18 years 
of age were 2.4 times more likely to receive 
a diagnosis of schizophrenia over the fol-
lowing 15 years compared to those who had 
not tried the drug (Andréasson et al., 1987). 
However, this study was not able to deter-
mine the direction of causality with respect 
to cannabis use and schizophrenia. Instead, 
the authors state: “Whether cannabis abuse 
preceded psychiatric symptoms in these cases 
or vice-versa cannot be determined” (An-
dréasson et al., 1987). Another follow-up of 
the Swedish cohort by Zammit and colleagues 
revealed a dose-response relationship between 
cannabis use at age 18 and schizophrenia risk 
(i.e., those who used the drug more frequently 
had higher risk), and the effect remained after 
controlling for various confounders including 
other substance use and certain features of 
family history and personality traits (Zammit 
et al., 2002). Notably, because this study only 
measures drug use at baseline, it is impossible 
to determine the patterns of drug use among 
study participants in the decades between the 
study’s baseline and emergence of schizophre-
nia. This introduces the potential for misclas-
sification bias into the study. 
Volkow and colleagues have noted the difficul-
ty of establishing causality in studies regarding 
cannabis use and mental illness, as a number 
of factors could predispose individuals to both 
(Volkow et al., 2014). For example, in a system-
atic review that included longitudinal and pop-
ulation-based studies on cannabis use and risk 
of psychotic outcomes, Moore and colleagues 
also found a dose-response effect of cannabis 
use on any psychotic outcomes, independent 
of other confounders and acute intoxication 
(Moore et al., 2007). However, they also noted 
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that observational studies cannot eliminate all 
confounders and that the uncertainty regard-
ing a direct causal relationship between canna-
bis use and psychosis is “unlikely to be re-
solved in the near future” (Moore et al., 2007). 
In an article that examined different hypoth-
eses about cannabis use and psychosis, Pierre 
notes that there are numerous factors that 
may increase the risk of psychosis; that the 
magnitude of risk from cannabis use appears 
“modest”; and that evidence is “equivocal” re-
garding the assumption that cannabis use “can 
cause schizophrenia” (Pierre, 2011).  Scientific 
findings are inconsistent on the magnitude of 
risk posed by cannabis use, as well as the fre-
quency or timing of use that is associated with 
mental illness (Andréasson et al., 1987; Caspi 
et al., 2005; Moore et al., 2007).
As Caspi and colleagues (2005) have noted, 
“the vast majority of young people who use 
cannabis do not develop psychosis” (Caspi et 
al., 2005). These authors and other available 
research have suggested that increased risk 
of psychosis from cannabis use may be most 
pronounced among people who are already 
genetically susceptible to such symptoms and 
schizophrenia (Henquet et al., 2008). Indeed, 
a recent study compared individuals who did 
and did not use cannabis (Proal et al., 2014). 
All participants then provided information 
about their family history of schizophrenia. 
The authors of the study found that while 
family history of schizophrenia predicted 
participant schizophrenia, cannabis use had 
no impact on increasing this risk. In short, the 
authors concluded that cannabis use by itself 
did not increase the risk of schizophrenia.
Out of all the evidence reviewed here in rela-
tion to claims about cannabis use and health 
effects, some of the strongest evidence (e.g., 
based on well-designed studies, etc.) supports 
an association between cannabis use and a risk 
of schizophrenia. However, as summarized 
above, a causal relationship between cannabis 
use and schizophrenia is not supported by the 
evidence (Advisory Council on the Misuse of 
Drugs, 2008).
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COMMON CLAIMS ON
CANNABIS REGULATION
COMMON CLAIMS ON CANNABIS REGULATION
CLAIM
STRENGTH OF 
SUPPORTING 
EVIDENCE
BOTTOM LINE
Legalization / regulation 
increases the availability 
of cannabis.
Weak
Evidence suggests that the supply of illegal can-
nabis has increased under a prohibition model, 
and that availability has remained high among 
youth. Evidence does not suggest that cannabis 
availability among youth has increased under 
regulatory systems.
“[I]f marijuana was legal-
ized, the increase in users 
would be both large and 
rapid…”
Weak
Evidence suggests that the policy environment 
(specifically legal status and enforcement policy) 
has at most a marginal impact on the prevalence 
of drug use, thereby suggesting that regulating 
cannabis markets will not inevitably cause high-
er levels of cannabis use.
Regulation will not re-
duce drug crime. Weak
Given that the prohibition of cannabis has not 
been shown to reduce illegal supply, it is likely 
that cannabis regulation is more effective at 
minimizing criminal markets for cannabis, de-
spite the fact that criminal markets will contin-
ue to represent a proportion of the total market.
“We are going to have a 
lot more people stoned 
on the highway and there 
will be consequences.”
Weak
While experimental studies suggest that canna-
bis intoxication reduces motor skills and likely 
increases the risk of motor vehicle collisions, 
there is not sufficient data to suggest that can-
nabis regulation would increase impaired driv-
ing, and thereby traffic fatalities.
Regulation promotes drug 
tourism. Weak
There is a great deal of uncertainty regarding 
cannabis regulation and so-called “drug tourism” 
and it is likely that such activity will vary across 
different jurisdictions based on the use of differ-
ent regulatory controls.
Regulation leads to a “Big 
Marijuana” scenario.
Weak
Available evidence regarding “Big Marijuana” 
is currently lacking, though regulatory controls 
can be introduced within regulatory systems to 
reduce the potential of profit maximization by 
cannabis retailers.
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CLAIM: Legalization / regulation increases the availability of cannabis.
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: Evidence suggests that the supply of illegal cannabis has increased under a 
prohibition model, and that availability has remained high among youth. Evidence does not 
suggest that cannabis availability among youth has increased under regulatory systems.
Over three decades of drug law enforcement, 
there is no evidence to suggest that the avail-
ability of cannabis has declined. Indeed, the 
opposite appears to be true. The availabili-
ty of illegal cannabis is difficult to quantify, 
given the obvious challenges in assessing the 
size and composition of illegal drug markets, 
and the fact that “availability” is a poorly and 
inconsistently defined variable. As such, gov-
ernments, law enforcement, and experts in the 
field have prioritized the use of two measures 
– price and purity – to assess changes in illicit 
drug markets. Assuming a constant demand, 
if the price of a drug drops and the purity of a 
drug increases, this suggests that the available 
of supply has increased. 
The United States provides a useful case study 
in this regard. Data suggest that the use of 
cannabis has remained relatively stable in the 
U.S. (UNODC, 2014). At the same time, as 
shown in Figure 2 below, the price of cannabis 
has dropped significantly in the U.S., while its 
potency has increased (Werb et al., 2013a).
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These trends in price and potency suggest that 
the supply of illicit cannabis has overwhelmed 
government supply reduction efforts, and in-
deed that it likely increased during this period, 
given that use remained relatively constant or 
increased (UNODC, 2014).  
Importantly, the ineffectiveness of enforce-
ment-based approaches for controlling canna-
bis supply in the U.S. affect young people in 
particular. The Monitoring the Future study 
is an annual surveillance study of drug and 
alcohol use among American youth. Every year 
since the beginning of the study in 1975, over 
80% of American grade 12 students – and in 
some years, over 90% – have consistently re-
ported that cannabis was “fairly easy” or “very 
easy” to obtain (Monitoring the Future, 2014). 
Similarly, in the European Union, research 
from 2014 indicates that 58% of young people 
aged 15 to 24 believe it would be either very 
easy or fairly easy to obtain cannabis within 24 
hours (European Commission, 2014).
Collectively, these data suggest that a system 
of drug prohibition has not been success-
ful at reducing the availability of cannabis, 
which has been more than able to keep pace 
with changes in demand. By contrast, it is 
noteworthy that levels of cannabis use in the 
Netherlands, where cannabis has been de facto 
legalized for decades, are estimated to be less 
than half of those in the United States in the 
period prior to state cannabis regulation (20% 
vs. 42%) (Degenhardt et al., 2008a), while it 
has similar or lower levels of use to neighbour-
ing European countries (EMCDDA, 2015). 
This implies that prohibition-based cannabis 
policies do not in and of themselves lead to 
lower levels of cannabis use.
In short, the evidence does not suggest that 
the availability, supply, or use of cannabis is 
meaningfully controlled by cannabis prohibi-
tion – at least not beyond marginal, localized 
and temporary impacts. Further, given that 
the regulatory systems for recreational can-
nabis have only recently been implemented 
in Colorado, Washington State, and Uruguay, 
it is too soon to tell what long-term impact 
these policy changes will have on cannabis 
availability. It is noteworthy, though, that drug 
regulation approaches provide a wide range 
of tools to policymakers – including bans on 
advertising, taxation, restrictions on licensing, 
and age restrictions – that have been shown 
to successfully limit access to tobacco among 
youth (Gutierrez and Pardo, 2015; Johnston et 
al., 2012).
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CLAIM: “[I]f marijuana was legalized, the increase in users would be both large and rapid…” – 
Robert L. DuPont 4
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: Evidence suggests that the policy environment (specifically legal status and 
enforcement policy) has at most a marginal impact on the prevalence of drug use, thereby sug-
gesting that regulating cannabis markets will not inevitably cause higher levels of cannabis use.
Some observers point to alcohol and tobac-
co use statistics to support claims that these 
substances are widely used due to their avail-
ability, and that cannabis use would therefore 
increase under a regulatory system. While 
alcohol and tobacco are legally regulated and 
indeed commonly used substances in many 
countries including Canada and the U.S., this 
does not necessarily mean that the population 
will experience a surge in cannabis use if the 
drug were regulated. 
Counterevidence to claims that regulation 
leads to increased use comes from a large 
study that examined drug use data across 17 
countries (combined sample size of 85,052 par-
ticipants) that took part in World Health Or-
ganization World Mental Health Surveys. In 
this study, Degenhardt and colleagues looked 
at lifetime use and age of first use of tobacco, 
alcohol, cannabis, and cocaine (Degenhardt et 
al., 2008b). The U.S. and New Zealand had the 
highest rates of cannabis use (42%) compared 
to other countries. The U.S. also stood out 
with greater levels of alcohol use and cocaine 
use, despite having a higher minimum legal 
drinking age and a more punitive illicit drug 
policy compared to many comparable devel-
oped nations. Compared to the U.S., the Neth-
erlands has much lower levels of cannabis use, 
especially among youth, despite having a de 
facto regulatory system for recreational canna-
bis. Overall, countries known to have stringent 
or punitive drug policies did not exhibit lower 
levels of drug use compared to countries with 
less stringent or more liberal policies. This 
pattern of findings led Degenhardt and col-
leagues to conclude that “by itself, a punitive 
policy towards possession and use accounts for 
limited variation in nation level rates of illegal 
drug use” (Degenhardt et al., 2008b). 
Various studies and surveillance reports com-
paring jurisdictions have highlighted the lack 
of correlation between legal status or harsh-
ness of law enforcement regimes, and levels 
of drug use (Degenhardt et al., 2008b; EM-
CDDA, 2015; Reinarman, 2009). In addition, 
longitudinal studies show no clear association 
between changes in cannabis policy and levels 
of use. For instance, a large national 15-year 
research study in the United States reported 
that medical marijuana systems has not led to 
increases in recreational adolescent cannabis 
use (Hasin et al., 2015). 
Over the last decade or so, several European 
countries have also changed their cannabis 
policies. Comparing prevalence estimates of 
cannabis use from before and after the policy 
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4 From a post titled, “Why We Should Not Legalize Marijuana” on the Illinois Church Action on Alcohol and 
Addiction Problems website. Accessed March 18th 2015 from http://ilcaaap.org/2011/06/22/why-we-should-not-legal-
ize-marijuana/
change can indicate whether there is an associ-
ation between the legal changes and cannabis 
use. 
Reproduced from the European Monitoring Centre for Drugs 
and Drugs Addiction (EMCDDA).
The graph above from the European Mon-
itoring Centre for Drugs and Drugs Addic-
tion (EMCDDA) plots changes in cannabis 
prevalence among 15 to 34 year olds against 
time (with zero representing the year of a 
legal change in cannabis policy) (EMCDDA, 
2011). The common legal hypothesis is that 
increased penalties will lead to a fall in drug 
use and reduced penalties to a rise in drug use. 
If this were true, countries where penalties 
increased (i.e., the dotted lines) would see de-
creases in cannabis use after the imposition of 
harsher legal sanctions, while countries where 
penalties decreased (i.e., the solid lines) would 
see rises in use after a reduction in legal sanc-
tions. As can be seen in the graph, and accord-
ing to the EMCDDA, “no simple association 
can be observed between legal changes and 
cannabis use prevalence ” (EMCDDA, 2011). 
Although the evidence that reducing penalties 
does not increase the prevalence of cannabis 
use is of significant importance, this does not 
necessarily predict that legal regulation will 
not lead to increases in use. Legal regulation 
necessarily opens up new sources of drug avail-
ability, and the way these sources are managed 
has the potential to generate sizeable changes 
in prevalence of use (Kilmer, 2010; Kilmer et 
al., 2010b). The use of stringent and respon-
sible regulatory controls, such as advertising 
bans and appropriate levels of taxation, are 
necessary to constrain any increases in con-
sumption. 
Some opponents to cannabis regulation have 
singled out use rates in U.S. states that have 
regulated recreational cannabis use. For ex-
ample, commentators have noted that, based 
on recent National Survey on Drug Use 
and Health (NSDUH) data, cannabis use in 
Colorado has risen between 2011-2012 and 
2012-2013, and that past-month and past-year 
cannabis use in the state has exceeded the 
national average, including use among adoles-
cents. However, it is important to note that 
legal sales of recreational cannabis to adults of-
ficially opened in Colorado at the start of 2014 
(Hopfer, 2014). Insufficient time has passed 
since the regulation of recreational cannabis 
use began in the state to adequately evaluate 
the impact of this policy shift on long-term 
cannabis use trends. It is also likely that indi-
viduals underreported their cannabis use prior 
to cannabis regulation given the stigma asso-
ciated with engaging in illegal drug use. In the 
short term, data on cannabis use among youth 
in Colorado suggests that use has stayed the 
same or even declined (especially when com-
paring data from the 1990s until the present) 
among teenagers in the years prior to formal 
regulation, while post-regulation data from 
the Colorado Department of Public Health 
and Environment have demonstrated that the 
use of cannabis by teenagers in Colorado has 
continued to decline after the legal reform 
(CDPHE, 2014).
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CLAIM: Regulation will not reduce drug crime.
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: Given that the prohibition of cannabis has not been shown to reduce illegal 
supply, it is likely that cannabis regulation is more effective at minimizing criminal markets for 
cannabis, despite the fact that criminal markets will continue to represent a proportion of the 
total market.
A commonly heard argument in favour of 
cannabis regulation is that it would reduce 
the violence associated with the illicit drug 
trade and the criminal justice resources spent 
on arresting and prosecuting drug offences. 
In response, opponents have countered that 
regulating cannabis will not reduce drug crime. 
To help bolster this claim, it has been reported 
that, for example, in recent years Colorado 
has witnessed significant increases in seizures 
of cannabis in mail parcels and other forms of 
transit that would have been diverted to other 
states (Rocky Mountain HIDTA, 2013). Media 
reports and groups like Smart Approaches to 
Marijuana have suggested that underground 
markets for cannabis thrive in Washington 
State and Colorado (Smart Approaches to 
Marijuana, 2015). As well, it has been estimat-
ed that Mexican drug cartels receive a minori-
ty of their revenue from cannabis and, as such, 
cannabis regulation would do little to reduce 
other illicit activities and crime related to oth-
er drugs (Kilmer et al., 2010a). 
Although illegal drug crime is still likely to 
continue under a regulated market, under 
prohibition-based systems, criminal markets 
control 100% of the cannabis market. By 
contrast, regulatory markets will divert at least 
a proportion of revenue towards legal mecha-
nisms. 
Overall, there is a lack of high-quality empir-
ical investigations to substantiate how much 
drug crime thrives under regulatory systems 
for recreational cannabis. Unfortunately, the 
situation in Netherlands is not very instruc-
tive since, due to their unusual legal approach, 
whilst the sales of cannabis from the ‘coffee 
shops’ is tolerated, supply to the ‘back door’ 
remains via criminal producers and suppliers. 
In Colorado and Washington State, insuffi-
cient time has passed since cannabis regu-
lation to adequately assess the situation. It 
is also difficult to study how much impact a 
change in drug legislation has on crime in gen-
eral and even drug crime specifically, as shifts 
in crime are subject to many factors, including 
social-structural changes. Additionally, crimi-
nal markets are notoriously difficult to quan-
tify. Nonetheless, regulated cannabis markets 
directly reduce some drug crime by removing 
the illegal nature of some forms of cannabis 
production, distribution, and consumption – 
assuming demand remains relatively constant. 
While observers argue that cannabis regula-
tion has not substantially reduced drug crime, 
evidence does not suggest that prohibition 
has been more effective. However, plenty of 
empirical evidence has accumulated demon-
strating the failures of drug prohibition and 
law enforcement when it comes to reducing 
the size of underground drug markets and 
trafficking. Werb and colleagues examined 
illicit drug supply indicators from government 
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surveillance system data and found evidence of 
decreasing prices for and increasing purity of 
heroin, cocaine, and cannabis over the last two 
decades (Werb et al., 2013a). At the same time, 
seizures of these drugs had typically increased 
or remained stable across global regions. 
Together these findings suggested a general 
increase in illegal supplies of these drugs, de-
spite continued international efforts focused 
on supply reduction. Also under prohibition, 
the illicit cannabis trade represents a highly 
lucrative criminal market (Kilmer and Pacula, 
2009). For a specific example, the domestic 
illicit cannabis trade in British Columbia is 
estimated to be between approximately $400 
million and $600 million annually (Werb et al., 
2012), while the pre-regulation illicit cannabis 
market in Washington State has been esti-
mated at approximately $300 million annu-
ally (Archambault et al., 2013). Regulation of 
recreational cannabis in Washington State has, 
at the very least, incorporated a substantial 
proportion of this illegal market into a regulat-
ed system.  
Finally, the notion that enforcement-based re-
sponses to illicit drug markets reduce the vio-
lence associated with criminal activity appears 
to be false. A recent systematic review evalu-
ated the impact of drug law enforcement on 
subsequent levels of drug-related and criminal 
violence (Werb et al., 2011). This review found 
that over 90% of scientific studies reported 
that violence increased as a result of drug law 
enforcement operations, and in many cases 
that this increase in violence was sustained for 
up to two years. These findings suggest that 
prohibition-based responses are unlikely to be 
more effective than regulatory approaches in 
reducing levels of violent drug crime.
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CLAIM: “We are going to have a lot more people stoned on the highway and there will be con-
sequences.” – Rep. John Mica (R-Fla.) 5
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: While experimental studies suggest that cannabis intoxication reduces motor 
skills and likely increases the risk of motor vehicle collisions, there is not sufficient data to sug-
gest that cannabis regulation would increase impaired driving, and thereby traffic fatalities.
Although evidence shows that the risk of 
motor vehicle collisions increases for driv-
ers during acute intoxication from cannabis 
use, evidence does not suggest that cannabis 
regulation leads to increases in the number of 
impaired drivers on the road.
A systematic review and meta-analysis of epi-
demiologic studies by Asbridge and colleagues 
is often cited to support the statement that 
cannabis use doubles the risk of a car crash 
(Asbridge et al., 2012). The Asbridge review 
included nine studies using control groups; 
all the studies were assessed as medium or 
high quality. Across most of these studies, 
driving under the influence of cannabis was 
associated with a significantly higher risk of 
crashing compared with driving unimpaired 
(Asbridge et al., 2012). Another meta-analy-
sis of epidemiologic studies similarly found 
that cannabis use increases the risk of motor 
vehicle collisions by more than 2-fold and in 
a dose-response manner (i.e., increasing dose 
and frequency of use increases crash risk) (Li 
et al., 2012). 
As such, while the evidence indicates that 
the risk of motor vehicle collisions increase 
for drivers during acute intoxication from 
cannabis use, there is no evidence to suggest 
that regulation of recreational cannabis will 
lead to an increase in persons driving while 
under the influence of cannabis. For example, 
recent data from Colorado provides reason 
to question any general claims that cannabis 
regulation will necessarily lead to less safety 
on the road at the population-level. As shown 
in the figure below, since the introduction of a 
regulatory system in 2012, traffic fatalities have 
actually decreased across the state. If cannabis 
regulation increased the risk of motor vehicle 
collisions as a result of more widespread use 
of cannabis, then we would expect that this              
Raw data from the Colorado Department of Transportation. 
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5 Reported in the Washington Post. Accessed March 18th 2015 from http://www.washingtonpost.com/news/the-
watch/wp/2014/08/05/since-marijuana-legalization-highway-fatalities-in-colorado-are-at-near-historic-lows/
would be borne out by the data. However, 
the opposite appears to be the case, with the 
post-regulation period in Colorado associated 
with lower levels of traffic fatalities (Colorado 
Department of Transportation, 2015). While 
the levels of total traffic fatalities may not tell 
us about the specific role of cannabis use in 
car crashes, they do suggest that cannabis reg-
ulation in Colorado has not led to less safety 
on the road at the population level. The falling 
rates of alcohol impaired driving fatalities also 
indicate that it is possible to prevent impaired 
driving, even for a legal drug. For instance, 
public education and awareness campaigns 
that are possible in a legally regulated market 
can certainly be valuable prevention inter-
ventions, as has occurred with drunk driving 
(Hingson and Winter, 2003). Similarly success-
ful initiatives could be used to prevent driving 
under the influence of cannabis. 
Importantly, by comparison, the risk of fatal 
crashes involving drivers with a Blood Alcohol 
Content (BAC) at 0.08% or above (i.e., the 
legal limit in many jurisdictions) was estimated 
to carry a 6-fold to a 241-fold increased risk 
compared with non-impaired drivers (Zador et 
al., 2000). Clearly, the risk of not only motor 
vehicle collisions, but fatal collisions, asso-
ciated with alcohol use is much higher than 
that associated with cannabis use. The impact 
of alcohol intoxication on driving therefore 
remains a far greater public health concern.
Finally, there are also some important limita-
tions of studies assessing motor impairment 
risk related to cannabis use. First, laboratory 
or experimental studies involving driving simu-
lators have reported that participants often 
compensate for impairment from cannabis use 
by driving more slowly (Hall, 2014; Hartman 
and Huestis, 2013). Some epidemiologic stud-
ies have only examined certain populations 
(e.g., people treated for substance use) or have 
not used appropriate controls (Hartman and 
Huestis, 2013). Importantly, as Li and col-
leagues noted, polydrug use (i.e., use of more 
than one drug) creates challenges in determin-
ing the precise risk associated with cannabis 
use (Li et al., 2012). Many impaired drivers test 
positive for more than one drug (including 
alcohol), which creates difficulties in interpret-
ing results in statistical models, given challeng-
es in disentangling the impact of the use of 
multiple drugs.
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CLAIM: Regulation promotes drug tourism. 6
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: There is a great deal of uncertainty regarding cannabis regulation and so-
called “drug tourism” and it is likely that such activity will vary across different jurisdictions 
based on the use of different regulatory controls.
While there are increasing media reports 
regarding recreational cannabis tourism in 
the United States (2015), there is a dearth of 
empirical evidence regarding whether or not 
regulation actually leads to increases in so-
called “drug tourism.” 
In a report about the potential impacts of 
cannabis legalization in California, Kilmer 
and colleagues stated that, “Marijuana legal-
ization would likely be a high-profile action, 
noted by people around the United States 
and even abroad. Plausibly, it could influence 
decisions to vacation in California” (Kilmer, 
2010). While these authors propose a hypo-
thetical increase in tourism post-legalization, 
they also note that they lack specific empiri-
cal justification for said figure. Reports about 
“drug tourism” have often made reference to 
cannabis selling at coffee shops in the Neth-
erlands. It has been estimated that of the 4.5 
million tourists who visit Amsterdam annually, 
approximately a quarter visit a coffee shop and 
that 10% of tourists say that use of cannabis 
in a coffee shop was their reason for visit-
ing the city (Kilmer, 2010), but it is unclear 
how systematically these data were collected. 
Further, it has been reported that the Dutch 
have become less tolerant of cannabis due to 
the coffee shops and that many of these es-
tablishments have been closed in recent years; 
however, even such reports have noted that 
the evidence on “drug tourism” is “sparse” 
(MacCoun, 2010). At the same time, there is 
little evidence suggesting that drug tourism 
contributes to widespread negative health or 
social outcomes in settings that have regulated 
cannabis. 
In a review article, Monshouwer and col-
leagues noted that there has been controversy 
in the Netherlands and that some municipali-
ties have had to address nuisance issues relat-
ed to “drug tourists” coming from Belgium, 
Germany, and France (Monshouwer et al., 
2011). This review also highlighted the ways in 
which regulatory policies can be changed or 
tightened (e.g., visitors would need a member-
ship card to purchase cannabis, strict limits 
on sale quantities, age restrictions at coffee 
shops, or restricting sales of cannabis to home 
country citizens) to discourage tourists, while 
still avoiding an enforcement-based model to 
control cannabis, which is likely less effective 
in reducing supply and availability (Monitoring 
the Future, 2014; Werb et al., 2013b). It is still 
too early to adequately assess whether locales 
that have recently regulated cannabis (i.e., 
Colorado, Washington State, and Uruguay) 
have witnessed negative “drug tourism” effects. 
However, as is evident from the Dutch ex-
perience, controls and new regulatory struc-
STATE OF THE EVIDENCE:
6 For example, see CBC news story. Accessed March 19th 2015 from http://www.cbc.ca/news/world/colora-
do-gets-high-on-pot-revenue-marijuana-tourists-1.2564410 
tures  can be introduced into existing systems 
in order to reduce the potential for negative 
impacts of drug tourism. Uruguay already has 
taken steps in this direction, as their regula-
tions only permit residents to grow and pur-
chase cannabis. This was an intentional policy 
decision made by the federal government to 
reduce the possibility that Uruguay would 
become a cannabis tourism destination (Guti-
errez & Pardo, 2015). 
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CLAIM: Regulation leads to a “Big Marijuana” scenario.
STRENGTH OF SUPPORTING EVIDENCE: Weak
BOTTOM LINE: Available evidence regarding “Big Marijuana” is currently lacking, though reg-
ulatory controls can be introduced within regulatory systems to reduce the potential of profit 
maximization by cannabis retailers.
Moves towards cannabis regulation in multiple 
U.S. states have prompted claims about regu-
lation ushering in a so-called “Big Marijuana” 
(less commonly, “Big Cannabis” or “Canna-
bis Inc.”) scenario. The basic premise is that 
cannabis regulation necessarily leads to a large, 
for-profit cannabis industry that features little 
oversight and lack of concern about public 
health and safety (Lopez, 2015) – echoing the 
negative influence of “Big Tobacco,” “Big Al-
cohol,” or “Big Pharma.” This claim is largely 
unsubstantiated by evidence, but reflects a 
reasonable concern that the implementation 
of for-profit systems for cannabis regulation 
incentivize the entry of aggressive private in-
terests seeking to maximize profit by selling as 
much cannabis as possible with little concerns 
for potential negative public health impacts. 
Tobacco was, in previous decades in North 
America, heavily advertised, and became a 
commonly used substance as well as a major 
source of preventable health conditions and 
mortality (Richter and Levy, 2014). Given this 
experience, it has been assumed that canna-
bis regulation will lead to a similar situation 
involving advertising (especially to youth) 
and industry deception about the health risks 
associated with cannabis use. These concerns, 
however, generally discuss “Big Marijuana” as a 
potential, rather than current, concern. This is 
a result of a lack of existing data from Amer-
ican states that have regulated cannabis. It is 
noteworthy that in the Netherlands, a state 
with longstanding de facto cannabis regula-
tion, few if any major concerns about “Big 
Marijuana” have been reported – though this 
may also be related to the fact that cannabis 
production is still technically criminalized in 
the Netherlands.
Concerns that regulation will inevitably lead 
to a “Big Marijuana” scenario imply a weaker 
level of government control than is possible 
under cannabis regulation. However, restric-
tions on advertising, requirements for product 
labelling on health harms, and investments in 
public education are regulatory controls that 
do not foster a large commercialized industry 
and can be adopted. In a comparative policy 
analysis of Colorado, Washington State, and 
Uruguay, Pardo briefly summarized numerous 
laws and regulations that place restrictions on, 
for example, retail quantities, age of purchase, 
commercial cultivation practices and process-
ing, advertising and promotion, and internet 
sales (Pardo, 2014). Uruguay, for example, has 
prohibited cannabis advertising (Pardo, 2014). 
In addition to the use of strict regulatory con-
trols, limiting market players can also diminish 
the likelihood of a “Big Marijuana” scenario. 
For instance, the size of markets in Spain and 
Belgium have been limited through the “can-
nabis social club” model, in which non-com-
mercial organizations are only legally allowed 
to cultivate and distribute cannabis to their 
members (Decorte, 2015). 
STATE OF THE EVIDENCE:
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